THERAPY DOSSIER · th-bfdd07bf20fd

Faecalibacterium prausnitzii strain A2-165 (probiotic)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 5

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06551272 ↗PHASE2recruiting

Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma (EXL01)

Hepatocellular Carcinoma

Enrolment: 34 · Results not recorded

NCT07128680 ↗PHASE1recruiting

Nivolumab and Ipilimumab With and Without EXL01 (F. prausnitzii strain formulation) in First-Line Metastatic Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell Carcinoma · Advanced Clear Cell Renal Cell Carcinoma

Enrolment: 33 · Results not recorded

NCT03728868 ↗NAcompleted

Tolerability and Risk of Adverse Events With a Probiotic Supplement (F. prausnitzii and D. piger) in Healthy Individuals

Healthy Individuals

Enrolment: 50 · Results not recorded

NCT04938843 ↗NAunknown

Effect of F. Prausnitzii on Glycemic Control - Randomized, Double Blind, Placebo-controlled Study

Pre Diabetes · Impaired Glucose Tolerance · Non-Alcoholic Fatty Liver Disease

Enrolment: 176 · Results not recorded

NCT07720362 ↗NAnot yet recruiting

Open-Label Trial of a Multi-Strain Commensal Probiotic Dietary Supplement on GI Microbiota Composition and Symptoms

Gastrointestinal · Microbiota

Enrolment: 25 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32985332 ↗2020Reported benefit

Prophylactic Faecalibacterium prausnitzii treatment prevents the acute breakdown of colonic epithelial barrier in a preclinical model of pelvic radiation disease

RatRadiationSprague DawleyMalen = Approximately 5-12 animals per group per experimental batchIntragastric (oral gavage)1x10^9 CFU administered intragastrically once dailyProphylactic: 3 days before irradiation, day of irradiation, and up to 2 days a…

Model: Single 29 Gy colorectal irradiation (pelvic radiation disease model)

Prophylactic F. prausnitzii treatment reduced radiation-induced histological damage, prevented acute paracellular hyperpermeability and neutrophil infiltration, increased resident macrophages, preserved Sox9+ stem/progenitor cells and Dclk1+/IL-25+ tuft cells, maintained epithelial proliferation an…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…